Application and safety of thalidomide in the treatment of multiple myeloma

研究成果: Review article査読

抄録

Thalidomide is now regarded as one of the most promising salvage therapies for refractory or relapsed multiple myeloma. Appropriate use of this drug is indispensable to avoid repeating drug-induced disaster. Recently, its application has been expanded from refractory or relapsed cases also to untreated patients or post transplanted cases. Thus, it should be clarified which population of the Japanese patients with myeloma may truly benefit by this drug. Guideline, recently established by the Japanese Society of Clinical Hematology, has functioned for safety use of this drug. For future approval by Japanese government, strict but well-organized system for safety applicable to the clinical setting in Japan is necessary.

本文言語English
ページ(範囲)2296-2301
ページ数6
ジャーナルNippon rinsho. Japanese journal of clinical medicine
65
12
出版ステータスPublished - 2007 12

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「Application and safety of thalidomide in the treatment of multiple myeloma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル